Five Prime Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue 13,791 9,983 64,916
Cost of Revenue - - -
Gross Profit 13,791 9,983 64,916
Operating Expenses
Research and Development 32,785 28,778 34,039
Sales, General and Admin. 10,427 9,009 11,216
Non-Recurring Items - - -
Other - - -
Operating Income (29,421) (27,804) 19,661
Income From Continuing Operations
Add'l Income/Expense Items 549 209 49
Earnings Before Interest and Tax (28,872) (27,595) 19,710
Interest Expense - - -
Earnings Before Tax (28,872) (27,595) 19,710
Income Tax - - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (28,872) (27,595) 19,710
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (28,872) (27,595) 19,710
Preferred Stock and Other Adjustments - - (18,823)
Net Income Applicable to Common Shareholders (28,872) (27,595) 887